What's in Fred Hutchinson Cancer Center's pipeline?

Fred Hutchinson Cancer Center has 14 drugs in our index: 7 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Fred Hutchinson Cancer Center's portfolio?

Top competitors by shared drug class: AbbVie, AbbVie Inc., Aclaris Therapeutics, Inc., Arcutis Biotherapeutics, Inc., Azienda Ospedaliero, Universitaria Pisana.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fred-hutchinson-cancer-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fred Hutchinson Cancer Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fred Hutchinson Cancer Center pipeline: 7 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 2 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Nicotine Lozenge	Nicotine Lozenge	marketed
Garlic oil	Garlic oil	marketed
Beta Carotene and Retinol	Beta Carotene and Retinol	marketed
Recombinant Granulocyte Colony-Stimulating Factor	Recombinant Granulocyte Colony-Stimulating Factor	marketed
Nicotine Gum	Nicotine Gum	marketed
JAK Inhibitor	JAK Inhibitor	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2	Oncology, Immunology
Atripla or Stribild	Atripla or Stribild	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase	Infectious Disease / Virology
endocrine-modulating drug therapy	endocrine-modulating drug therapy	phase 3	Endocrine modulator		Oncology
Liposome-encapsulated Daunorubicin-Cytarabine	Liposome-encapsulated Daunorubicin-Cytarabine	phase 3	Liposomal chemotherapy combination	DNA (topoisomerase II for daunorubicin; DNA polymerase for cytarabine)	Oncology

Therapeutic area mix

Oncology · 2
Other · 2
Infectious Disease / Virology · 1
Oncology, Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie · 1 shared drug class
AbbVie Inc. · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class
Arcutis Biotherapeutics, Inc. · 1 shared drug class
Azienda Ospedaliero, Universitaria Pisana · 1 shared drug class
Beijing Friendship Hospital · 1 shared drug class
CAGE Bio Inc. · 1 shared drug class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fred Hutchinson Cancer Center:

Cite this brief

Drug Landscape (2026). Fred Hutchinson Cancer Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fred-hutchinson-cancer-center. Accessed 2026-05-17.